The Spanish biotechnological company, Ikan Biotech, has finished its financing round with €750,000 thanks to the support of 36 investors and lead investors. XtartCube and Chamberí Ventures trusted this project from the beginning and they have been the lead investors in this round. Their researches, based on tests with zebrafish, will allow to reduce the performance time and detect the best personalized treatment against colon and lung cancer, key factors for their cure. Madrid – 9 September 2020. Ikan Biotech is a Spanish company from the biotechnological sector, focused on the colon and lung cancer research. Their innovative proposal consists of using zabrafish, an animal with which the human being shares 87% of their genome. The zebrafish is used as a human avatar for the clinical tests performace, from a biopsy taken from the patient, allowing doctors to analyze the evolution of different types of treatment with the aim of choosing the best for the patient who suffer colon or lung cancer. Ikan Biotech has finished a financing round which allow them to improve their research, through our Equity Crowdfunding platform. The main goal of Ikan Biotech is to collect €400,000. However, thos amount increase up to €600,000 thanks to the interest of several investors. Finally, they got €750,00 (125%) thanks to the support of 36 investors. The round had 2 lead investors: XtartCube and Chamberí Ventures, who trsuted this project from the beginning. Thanks yo this financing round, this Spanish company can continue their research in lung and colon cancer and start new tests on their technology soon. Therefore, they can help improve oncological treatments, especially colon cancer, that, According to Asociación Española Contra el Cáncer, 1 out of 20 men and 1 out of 30 women suffer before being 74. In Spain, among those diagnosed, the average survival rate at 5 years is 64%. According to experts, in this type of disease, early detection and, above all, personalized treatment are key to survival. Thanks to Ikan Biotech, costs and time will be reduced in the identification of the best individualized treatment within 2 to 4 weeks as opposed to the 3 to 4 months it would take to perform the same tests on mice. As a result, colon cancer’s mortality rate could decrease considerably, and Ikan Biotech contributes a really positive social impact. Fellow Funders keep supporting innovative projects with a clear social component and with a high growth potential. The Ikan Biotech round through Fellow Funders confirms the ESG strategic trend, which takes already part of our NDA.
